TY - JOUR
T1 - The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer
T2 - a prospective evaluation in 100 patients undergoing radical prostatectomy.
AU - Mao, Kaili
AU - Badoual, Cécile
AU - Camparo, Philippe
AU - Delongchamps, Nicolas Barry
AU - Vieillefond, Annick
AU - Dinh-Xuan, Anh Tuan
AU - Peyromaure, Michaël
PY - 2008/1/1
Y1 - 2008/1/1
N2 - OBJECTIVES: To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer. METHODS: One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed. RESULTS: After a median follow-up of 22 months, 14 patients experienced biological recurrence of prostate cancer. There was no correlation between plasma VEGF-A and the risk of recurrence following RP. Moreover, there was no correlation between VEGF-A expression or VEGFR-1 expression in prostate cancer tissue and the risk of recurrence after RP. CONCLUSIONS: Plasma levels of VEGF-A, the expression of VEGF-A and that of VEGFR-1 in prostate cancer tissue did not affect patients outcome following RP. VEGF-A and its receptor VEGFR-1 may have no prognostic value in localized prostate cancer. Further studies with longer follow-up are mandatory to confirm these findings.
AB - OBJECTIVES: To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer. METHODS: One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed. RESULTS: After a median follow-up of 22 months, 14 patients experienced biological recurrence of prostate cancer. There was no correlation between plasma VEGF-A and the risk of recurrence following RP. Moreover, there was no correlation between VEGF-A expression or VEGFR-1 expression in prostate cancer tissue and the risk of recurrence after RP. CONCLUSIONS: Plasma levels of VEGF-A, the expression of VEGF-A and that of VEGFR-1 in prostate cancer tissue did not affect patients outcome following RP. VEGF-A and its receptor VEGFR-1 may have no prognostic value in localized prostate cancer. Further studies with longer follow-up are mandatory to confirm these findings.
UR - http://www.scopus.com/inward/record.url?scp=55249117543&partnerID=8YFLogxK
M3 - Article
C2 - 18814815
AN - SCOPUS:55249117543
SN - 1195-9479
VL - 15
SP - 4257
EP - 4262
JO - The Canadian journal of urology
JF - The Canadian journal of urology
IS - 5
ER -